ðŸ“„ TLF Specification for Study WO41554 (INAVO120)

Study Title:
Phase III, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Inavolisib Plus Palbociclib and Fulvestrant in PIK3CA-Mutant, HR-Positive, HER2-Negative Breast Cancer

Sponsor: F. Hoffmann-La Roche Ltd
SAP Version: 2
SAP Date: 18-Sep-2023

â¸»

1. Tables

1.1 Demographics and Baseline Characteristics
	â€¢	T001: Demographic summary (age, sex, race, ethnicity)
	â€¢	T002: Baseline disease characteristics (visceral disease, ECOG, hormone receptor status)
	â€¢	T003: Prior treatment history and endocrine resistance
	â€¢	T004: Stratification factors by treatment arm

1.2 Study Conduct
	â€¢	T005: Patient disposition
	â€¢	T006: Reasons for study and treatment discontinuation
	â€¢	T007: Protocol deviations (major/minor)
	â€¢	T008: Study treatment exposure (cycles, duration, dose intensity)

1.3 Efficacy â€” Primary Endpoint (PFS)
	â€¢	T101: PFS â€” HR, 95% CI, p-value (stratified and unstratified)
	â€¢	T102: Median PFS (months) with 95% CI by treatment arm
	â€¢	T103: Number of PFS events and censored observations
	â€¢	T104: Sensitivity analyses (BICR, stratified/unstratified, PIK3CA-confirmed subgroup)
	â€¢	T105: Supplementary analyses (hypothetical and composite ICE strategies)
	â€¢	T106: PFS subgroup analysis (HR and 95% CI per subgroup)

1.4 Efficacy â€” Secondary Endpoints
	â€¢	T201: OS summary (stratified HR, median OS, events, CI)
	â€¢	T202: ORR summary (CR + PR) â€” response rate, 95% CI, difference
	â€¢	T203: BOR summary (CR + PR) â€” response rate, 95% CI, difference
	â€¢	T204: CBR summary (CR + PR + SD â‰¥24 weeks)
	â€¢	T205: Duration of Objective Response â€” HR, median DOR, 95% CI (descriptive only)

1.5 Efficacy â€” PRO/TTCD Endpoints
	â€¢	T301: TTCD in pain (BPI-SF) â€” KM estimate, HR, median
	â€¢	T302: TTCD in physical function (QLQ-C30 items 1â€“5)
	â€¢	T303: TTCD in role function (QLQ-C30 items 6â€“7)
	â€¢	T304: TTCD in GHS/HRQoL (QLQ-C30 items 29â€“30)

1.6 Exploratory Efficacy
	â€¢	T401: Time to end of next-line treatment (proxy PFS2)
	â€¢	T402: Time to first skeletal-related event (SRE)

1.7 Patient-Reported Outcomes (PRO)
	â€¢	T501: Summary of BPI-SF and QLQ-C30/BR23 mean scores at each time point
	â€¢	T502: Mean change from baseline for all QLQ scales with 95% CI
	â€¢	T503: PRO compliance and completion rates by visit

1.8 Safety
	â€¢	T601: Incidence of AEs, SAEs, AESIs (by system organ class and preferred term)
	â€¢	T602: AEs by severity (CTCAE v5.0 grade)
	â€¢	T603: AEs leading to dose reduction, interruption, or discontinuation
	â€¢	T604: Summary of vital signs changes
	â€¢	T605: Summary of ECG changes
	â€¢	T606: Summary of laboratory abnormalities (shift tables, worst grade)
	â€¢	T607: Hy's Law analysis

1.9 Exploratory Safety (PRO-CTCAE)
	â€¢	T701: Frequency, severity, interference for each PRO-CTCAE symptom item
	â€¢	T702: "Bother from side effects" summary
	â€¢	T703: Summary of missing data in PRO-CTCAE

1.10 PK / Biomarker / Utility / China Subpopulation
	â€¢	T801: PK summary statistics (Cmax, Tmax, AUC) by treatment arm
	â€¢	T802: Exploratory biomarker summaries (as applicable)
	â€¢	T803: EQ-5D-5L summary statistics
	â€¢	T804: China subpopulation efficacy and safety tables (replicates of main analyses)

â¸»

2. Listings

2.1 Patient Listings
	â€¢	L001: Patient disposition
	â€¢	L002: Inclusion/exclusion criteria violations
	â€¢	L003: Protocol deviations
	â€¢	L004: Randomization and stratification

2.2 Efficacy Listings
	â€¢	L101: PFS, OS, ORR, BOR, CBR results by patient
	â€¢	L102: TTCD dates and scores by patient
	â€¢	L103: QLQ-C30 and QLQ-BR23 raw scores and transformation

2.3 Safety Listings
	â€¢	L201: All AEs and SAEs
	â€¢	L202: AESIs
	â€¢	L203: AEs leading to study drug modification
	â€¢	L204: Laboratory results (including shifts)
	â€¢	L205: Vital signs and ECG values
	â€¢	L206: Deaths and cause of death

2.4 PRO-CTCAE Listings
	â€¢	L301: Individual PRO-CTCAE items
	â€¢	L302: Maximum post-baseline score by patient

2.5 Pharmacokinetics and Biomarkers
	â€¢	L401: Individual plasma concentrations for inavolisib, palbociclib, fulvestrant
	â€¢	L402: Intense PK data for Chinese patients
	â€¢	L403: Biomarker results by patient and specimen

â¸»

3. Figures

3.1 Efficacy Figures
	â€¢	F101: Kaplan-Meier plot of PFS by treatment arm
	â€¢	F102: KM plot for OS
	â€¢	F103: KM plots for TTCD endpoints (pain, PF, RF, GHS/HRQoL)
	â€¢	F104: Forest plot of PFS subgroup analysis
	â€¢	F105: KM plots for DOR and PFS2 (exploratory)

3.2 Safety and PRO Figures
	â€¢	F201: AE summary bar chart (preferred term â‰¥10%)
	â€¢	F202: Laboratory shift plots for key parameters
	â€¢	F203: Line plots of mean PRO scores over time (QLQ-C30 and BR23)
	â€¢	F204: PRO-CTCAE bar/line plots (frequency/severity over time)

3.3 PK Figures
	â€¢	F301: Concentration-time curves (mean + SD)
	â€¢	F302: Individual PK plots for intense sampling
